Actress And Osteoporosis Advocate Sally Field Salutes Women's Health Innovators And Encourages American Women To 'Rally With Sally' For Bone Health

In a ceremony today, at the first
annual Ladies' Home Journal Health Breakthrough Awards, Sally Field,
Oscar-winning actress and advocate for osteoporosis education, honored
medical professionals whose breakthroughs have benefited women's health.



"For me personally and for so many other women, the dedicated efforts
of these medical professionals have given us chances that our mothers and
grandmothers never had in facing diseases head on, and thriving," said
Field, who was diagnosed with osteoporosis in 2005. At that time, Field
began an active osteoporosis management program and treats her condition
with once-monthly Boniva(R) (ibandronate sodium), a prescription medicine
for postmenopausal osteoporosis.


A baby boomer who turns 60 in November, Field continues to lead an
active life -- including filming her upcoming fall show "Brothers &
Sisters," which will air on ABC, and rallying women nationwide to work
toward better bone health at BoneHealth and 877-BoneHealth.


"Already 50,000 Web visitors have joined me online to learn how to
treat their bones right. It's important to keep the momentum, so I'm
encouraging women to tell their friends and family members about
BoneHealth. Helping more women learn about osteoporosis and how to
maintain good bone health is what it's all about," she said. The Rally With
Sally For Bone Health(SM) campaign is sponsored by Roche and
GlaxoSmithKline.


Field presented honors to the medical professionals at the Ladies' Home
Journal Health Breakthrough Awards in Manhattan. Created to recognize
medical professionals whose work has improved women's lives, the awards
were given to:


-- Frank Speizer, M.D., and Walter Willett, M.D., both of Harvard Medical
School, for their work with The Nurses Health Study, which has examined
chronic diseases in women over the past 30 years, including
osteoporosis


-- Deborah K. Armstrong, M.D., of Johns Hopkins School of Medicine,
Baltimore, for her research into ovarian cancer



-- Susan Cu-Uvin, M.D., of Brown Medical School, for setting up the
nation's first HIV/AIDS menopause clinic


-- Mary Ann Keenan, M.D., of University of Pennsylvania, for pioneering
surgical techniques that relieve musculo/skeletal deformities brought
on by stroke


-- Etta Pisano, M.D., of University of North Carolina, for research into
digital mammograms, and


-- Marianne Legato, M.D., of Columbia University, for helping to establish
and promote gender-specific medicine.















The Ladies' Home Journal Health Breakthrough Awards are sponsored by
GlaxoSmithKline.


About Boniva(R) (ibandronate sodium)


Boniva Tablets are contraindicated in patients unable to stand or sit
upright for at least 60 minutes, with uncorrected hypocalcemia, or with
known hypersensitivity to any component of Boniva. Boniva, like other
bisphosphonates administered orally, may cause upper gastrointestinal
disorders such as dysphagia, esophagitis, and esophageal or gastric ulcer.
Boniva is not recommended in patients with severe renal impairment.
Adequate intake of calcium and vitamin D is important in all patients.


Patients have reported severe bone, joint and/or muscle pain after
taking bisphosphonate therapy for osteoporosis. Additionally, osteonecrosis
of the jaw has been reported in patients treated with bisphosphonates; most
cases have been in cancer patients undergoing dental procedures.


The most commonly reported adverse events with once-monthly Boniva
regardless of causality were abdominal pain (Boniva 150 mg 7.8 percent vs.
Boniva 2.5 mg 5.3 percent), hypertension (6.3 percent vs. 7.3 percent),
dyspepsia (5.6 percent vs. 7.1 percent), arthralgia (5.6 percent vs. 3.5
percent), nausea (5.1 percent vs. 4.8 percent) and diarrhea (5.1 percent
vs. 4.1 percent). For complete prescribing information for Boniva, see
contact information at the end of the news release or go to
boniva.


About Roche and GlaxoSmithKline


Hoffmann-La Roche, Inc. (Roche) and GlaxoSmithKline (GSK) have a
worldwide collaboration (excluding Japan) to promote Boniva for the
treatment and prevention of postmenopausal osteoporosis.
Roche is one of the world's leading innovation-driven healthcare
groups. Its core businesses are pharmaceuticals and diagnostics. Roche has
alliances and research and development agreements with numerous partners,
including majority ownership interests in Genentech and Chugai. For further
information, visit rocheusa.


GSK, one of the world's leading research-based pharmaceutical and
healthcare companies, is committed to improving the quality of human life
by enabling people to do more, feel better and live longer. For company
information, visit GSK on the World Wide Web at gsk.


Boniva is a registered trademark of Roche Therapeutics, Inc. Rally With
Sally For Bone Health is a service mark of Roche Therapeutics, Inc.
For more information or full prescribing information, contact:


Roche; GSK

BoneHealth


View drug information on Boniva.